186 related articles for article (PubMed ID: 25093583)
21. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
[TBL] [Abstract][Full Text] [Related]
22. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
[TBL] [Abstract][Full Text] [Related]
23. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
Jahchan NS; Dudley JT; Mazur PK; Flores N; Yang D; Palmerton A; Zmoos AF; Vaka D; Tran KQ; Zhou M; Krasinska K; Riess JW; Neal JW; Khatri P; Park KS; Butte AJ; Sage J
Cancer Discov; 2013 Dec; 3(12):1364-77. PubMed ID: 24078773
[TBL] [Abstract][Full Text] [Related]
24. Drug repurposing in cancer.
Sleire L; Førde HE; Netland IA; Leiss L; Skeie BS; Enger PØ
Pharmacol Res; 2017 Oct; 124():74-91. PubMed ID: 28712971
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
26. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
[TBL] [Abstract][Full Text] [Related]
28. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
29. Repurposing of approved cardiovascular drugs.
Ishida J; Konishi M; Ebner N; Springer J
J Transl Med; 2016 Sep; 14():269. PubMed ID: 27646033
[TBL] [Abstract][Full Text] [Related]
30. Orabase-formulated gentian violet effectively improved oral potentially malignant disorder in vitro and in vivo.
Wang YY; Xiao LY; Wu PC; Chen YK; Lo S; Hu SCS; Chen YH; Chiu CCC; Yuan SSF
Biochem Pharmacol; 2020 Jan; 171():113713. PubMed ID: 31733192
[TBL] [Abstract][Full Text] [Related]
31. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Volpin F; Casaos J; Sesen J; Mangraviti A; Choi J; Gorelick N; Frikeche J; Lott T; Felder R; Scotland SJ; Eisinger-Mathason TSK; Brem H; Tyler B; Skuli N
Oncogene; 2017 May; 36(21):3037-3047. PubMed ID: 27941882
[TBL] [Abstract][Full Text] [Related]
32. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
[TBL] [Abstract][Full Text] [Related]
33. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
34. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
[TBL] [Abstract][Full Text] [Related]
35. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
36. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.
Li B; Flaveny CA; Giambelli C; Fei DL; Han L; Hang BI; Bai F; Pei XH; Nose V; Burlingame O; Capobianco AJ; Orton D; Lee E; Robbins DJ
PLoS One; 2014; 9(7):e101969. PubMed ID: 25003333
[TBL] [Abstract][Full Text] [Related]
37. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
Jun HT; Sun J; Rex K; Radinsky R; Kendall R; Coxon A; Burgess TL
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6735-42. PubMed ID: 18006775
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.
David CN; Frias ES; Elix CC; McGovern KE; Walker AM; Eichler JF; Wilson EH
ASN Neuro; 2015; 7(1):. PubMed ID: 25732707
[TBL] [Abstract][Full Text] [Related]
39. Drug Repurposing in Anticancer Reagent Development.
Chen PC; Liu X; Lin Y
Comb Chem High Throughput Screen; 2017; 20(5):395-402. PubMed ID: 28025934
[TBL] [Abstract][Full Text] [Related]
40. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
